{"id":948637,"date":"2026-04-02T09:06:17","date_gmt":"2026-04-02T13:06:17","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-begins-treating-patients-in-phase-3-rasolute-303-trial-evaluating-daraxonrasib-as-first-line-treatment-for-patients-with-metastatic-pancreatic-cancer\/"},"modified":"2026-04-02T09:06:17","modified_gmt":"2026-04-02T13:06:17","slug":"revolution-medicines-begins-treating-patients-in-phase-3-rasolute-303-trial-evaluating-daraxonrasib-as-first-line-treatment-for-patients-with-metastatic-pancreatic-cancer","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-begins-treating-patients-in-phase-3-rasolute-303-trial-evaluating-daraxonrasib-as-first-line-treatment-for-patients-with-metastatic-pancreatic-cancer\/","title":{"rendered":"Revolution Medicines Begins Treating Patients in Phase 3 RASolute 303 Trial Evaluating Daraxonrasib as First Line Treatment for Patients with Metastatic Pancreatic Cancer\u00a0"},"content":{"rendered":"
\n

REDWOOD CITY, Calif., April 02, 2026 (GLOBE NEWSWIRE) — Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it has begun treating patients in RASolute 303, a global Phase 3 clinical trial evaluating daraxonrasib as monotherapy and in combination with chemotherapy in patients with previously untreated metastatic pancreatic ductal adenocarcinoma (PDAC), a disease predominantly driven by oncogenic RAS variants. RASolute 303 is designed to enroll patients irrespective of tumor RAS genotype.\u00a0<\/p>\n

\u201cStarting treatment of study participants in the RASolute 303 trial represents an important milestone for our daraxonrasib program and for patients with metastatic pancreatic cancer, a disease with substantial unmet medical need,\u201d said Alan Sandler, M.D., chief development officer of Revolution Medicines. \u201cIn this trial, we are testing two biologically rational approaches\u2014daraxonrasib as monotherapy and daraxonrasib in combination with chemotherapy\u2014as two distinct, promising strategies to potentially improve patient outcomes. This trial underscores our commitment to advancing RAS(ON) inhibition into earlier lines of therapy, where we believe it can deliver significant benefit.\u201d<\/p>\n

RASolute\u00a0303 (NCT07491445)<\/a>\u00a0is a global, randomized, open-label Phase 3 trial evaluating\u00a0daraxonrasib\u00a0as monotherapy or in combination with gemcitabine and nab-paclitaxel versus standard-of-care gemcitabine and nab-paclitaxel in patients with previously untreated metastatic\u00a0PDAC. In this trial, the company is\u00a0enrolling patients who have not received prior systemic therapy for metastatic disease. The primary endpoints are progression-free survival and overall survival. Key secondary endpoints include additional measures of antitumor activity, safety and tolerability, and patient reported outcomes.\u00a0<\/p>\n

Daraxonrasib\u00a0is currently being evaluated in four global Phase 3 registrational trials, including three trials in patients with PDAC and one in patients with non-small cell lung cancer (NSCLC).\u00a0<\/p>\n

\n About Pancreatic Cancer and Pancreatic Ductal Adenocarcinoma<\/strong>\u00a0
Pancreatic cancer is one of the most lethal malignancies, characterized by its typically late-stage diagnosis, resistance to standard chemotherapy, and high mortality rate. In the U.S., recent estimates\u00a0indicate\u00a0that\u00a0approximately 60,000\u00a0people are diagnosed annually with pancreatic cancer, and about 50,000 people will die from this aggressive\u00a0disease.1<\/sup>\u00a0<\/p>\n

Due to the lack of early symptoms and detection methods, approximately 80% of patients are diagnosed with PDAC at an advanced or metastatic stage. It is the most commonly RAS-driven malignancy of all major cancers, and more than 90% of patients have tumors that harbor RAS\u00a0mutations.2<\/sup>\u00a0Metastatic PDAC\u00a0remains\u00a0one of the most common causes of cancer-related deaths in the U.S., with a five-year survival rate of approximately 3%.\u00a03<\/sup>,<\/sup>4<\/sup>\u00a0<\/p>\n

\n About\u00a0Daraxonrasib<\/strong>\u00a0
Daraxonrasib (RMC-6236) is an oral, direct RAS(ON) multi-selective inhibitor with the potential to help address a broad range of cancers driven by oncogenic RAS, including PDAC, NSCLC and colorectal cancer. Daraxonrasib suppresses RAS signaling by blocking the interaction of wild-type and mutant RAS(ON) with its downstream effectors.<\/p>\n

\n About Revolution Medicines, Inc.
<\/strong>Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company\u2019s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company\u2019s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Additional development opportunities in the company\u2019s pipeline focus on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C). For more information, please visit www.revmed.com<\/a> and follow us on LinkedIn<\/a>.<\/p>\n

\n Forward Looking Statements<\/strong>\u00a0<\/p>\n

\n This press release\u00a0contains\u00a0forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered “forward-looking statements,” including without limitation statements regarding progression of clinical studies and findings from these studies, including the safety, tolerability and antitumor activity of the company\u2019s candidates being studied and the durability of these results; dosing and enrollment in the company\u2019s clinical trials;\u00a0and the company\u2019s ability to improve patient outcomes or advance RAS(ON) inhibition into earlier lines of therapy.\u00a0Forward-looking statements are typically, but not always, identified by the use of words such as “may,” “will,” “would,” “believe,” “intend,” “plan,” “anticipate,” “estimate,” “expect,” and other similar terminology indicating future results.\u00a0Such forward-looking statements are subject to substantial risks and uncertainties that could cause the company\u2019s development programs, future results,\u00a0performance\u00a0or achievements to differ materially from those\u00a0anticipated\u00a0in the forward-looking statements. Such risks and uncertainties include without limitation risks and uncertainties inherent in the drug development process, including the company\u2019s programs\u2019 current stage of development, the process of designing and conducting preclinical and clinical trials, risks that the results of prior clinical trials may not be predictive of future clinical trials, clinical efficacy, or other future results, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, the company\u2019s ability to successfully establish, protect and defend its intellectual property, other matters that could affect the sufficiency of the company\u2019s capital resources to fund operations, reliance on third parties for manufacturing and development efforts, changes in the competitive landscape, and the effects on the company\u2019s business of the global events, such as international conflicts or global pandemics. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Revolution Medicines in general, see Revolution Medicines\u2019 Annual Report on Form 10-K filed with the Securities and Exchange Commission (the \u201cSEC\u201d) on February 25, 2026, and its future periodic reports to be filed with the SEC. Except as required by law, Revolution Medicines undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.<\/em>\u00a0<\/p>\n

\n Revolution Medicines Media & Investor Contact:<\/strong>\u00a0
media@revmed.com<\/u><\/a>
investors@revmed.com<\/u><\/a>\u00a0<\/p>\n

\n 1<\/sup> Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024.\u00a0CA Cancer J Clin<\/em>. 2024;74(1):12-49. doi:10.3322\/caac.21820
2<\/sup> Lee JK, Sivakumar S, Schrock AB, et al. Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors. NPJ Precis Oncol.<\/em> 2022;6(1);91. doi:10.1038\/s41698-022-00334-z
3<\/sup> Halbrook CJ, Lyssiotis CA, Pasca di Magliano M, Maitra A. Pancreatic cancer: Advances and challenges. Cell.<\/em> 2023;186(8):1729-1754. doi:10.1016\/j.cell.2023.02.014
4<\/sup> American Cancer Society. Survival rates for pancreatic cancer. Available at: https:\/\/www.cancer.org\/cancer\/types\/pancreatic-cancer\/detection-diagnosis-staging\/survival-rates.html. Accessed February 2026.<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

REDWOOD CITY, Calif., April 02, 2026 (GLOBE NEWSWIRE) — Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it has begun treating patients in RASolute 303, a global Phase 3 clinical trial evaluating daraxonrasib as monotherapy and in combination with chemotherapy in patients with previously untreated metastatic pancreatic ductal adenocarcinoma (PDAC), a disease predominantly driven by oncogenic RAS variants. RASolute 303 is designed to enroll patients irrespective of tumor RAS genotype.\u00a0 \u201cStarting treatment of study participants in the RASolute 303 trial represents an important milestone for our daraxonrasib program and for patients with metastatic pancreatic cancer, a disease with substantial unmet medical need,\u201d said Alan Sandler, M.D., chief development officer of … <\/p>\n

Continue reading “Revolution Medicines Begins Treating Patients in Phase 3 RASolute 303 Trial Evaluating Daraxonrasib as First Line Treatment for Patients with Metastatic Pancreatic Cancer\u00a0“<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-948637","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nRevolution Medicines Begins Treating Patients in Phase 3 RASolute 303 Trial Evaluating Daraxonrasib as First Line Treatment for Patients with Metastatic Pancreatic Cancer\u00a0 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-begins-treating-patients-in-phase-3-rasolute-303-trial-evaluating-daraxonrasib-as-first-line-treatment-for-patients-with-metastatic-pancreatic-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Revolution Medicines Begins Treating Patients in Phase 3 RASolute 303 Trial Evaluating Daraxonrasib as First Line Treatment for Patients with Metastatic Pancreatic Cancer\u00a0 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"REDWOOD CITY, Calif., April 02, 2026 (GLOBE NEWSWIRE) — Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it has begun treating patients in RASolute 303, a global Phase 3 clinical trial evaluating daraxonrasib as monotherapy and in combination with chemotherapy in patients with previously untreated metastatic pancreatic ductal adenocarcinoma (PDAC), a disease predominantly driven by oncogenic RAS variants. RASolute 303 is designed to enroll patients irrespective of tumor RAS genotype.\u00a0 \u201cStarting treatment of study participants in the RASolute 303 trial represents an important milestone for our daraxonrasib program and for patients with metastatic pancreatic cancer, a disease with substantial unmet medical need,\u201d said Alan Sandler, M.D., chief development officer of … Continue reading "Revolution Medicines Begins Treating Patients in Phase 3 RASolute 303 Trial Evaluating Daraxonrasib as First Line Treatment for Patients with Metastatic Pancreatic Cancer\u00a0"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-begins-treating-patients-in-phase-3-rasolute-303-trial-evaluating-daraxonrasib-as-first-line-treatment-for-patients-with-metastatic-pancreatic-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-02T13:06:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4MzI1MyM3NDkzNTEyIzIxOTQwMzQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolution-medicines-begins-treating-patients-in-phase-3-rasolute-303-trial-evaluating-daraxonrasib-as-first-line-treatment-for-patients-with-metastatic-pancreatic-cancer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolution-medicines-begins-treating-patients-in-phase-3-rasolute-303-trial-evaluating-daraxonrasib-as-first-line-treatment-for-patients-with-metastatic-pancreatic-cancer\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Revolution Medicines Begins Treating Patients in Phase 3 RASolute 303 Trial Evaluating Daraxonrasib as First Line Treatment for Patients with Metastatic Pancreatic Cancer\u00a0\",\"datePublished\":\"2026-04-02T13:06:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolution-medicines-begins-treating-patients-in-phase-3-rasolute-303-trial-evaluating-daraxonrasib-as-first-line-treatment-for-patients-with-metastatic-pancreatic-cancer\\\/\"},\"wordCount\":1079,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolution-medicines-begins-treating-patients-in-phase-3-rasolute-303-trial-evaluating-daraxonrasib-as-first-line-treatment-for-patients-with-metastatic-pancreatic-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4MzI1MyM3NDkzNTEyIzIxOTQwMzQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolution-medicines-begins-treating-patients-in-phase-3-rasolute-303-trial-evaluating-daraxonrasib-as-first-line-treatment-for-patients-with-metastatic-pancreatic-cancer\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolution-medicines-begins-treating-patients-in-phase-3-rasolute-303-trial-evaluating-daraxonrasib-as-first-line-treatment-for-patients-with-metastatic-pancreatic-cancer\\\/\",\"name\":\"Revolution Medicines Begins Treating Patients in Phase 3 RASolute 303 Trial Evaluating Daraxonrasib as First Line Treatment for Patients with Metastatic Pancreatic Cancer\u00a0 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolution-medicines-begins-treating-patients-in-phase-3-rasolute-303-trial-evaluating-daraxonrasib-as-first-line-treatment-for-patients-with-metastatic-pancreatic-cancer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolution-medicines-begins-treating-patients-in-phase-3-rasolute-303-trial-evaluating-daraxonrasib-as-first-line-treatment-for-patients-with-metastatic-pancreatic-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4MzI1MyM3NDkzNTEyIzIxOTQwMzQ=\",\"datePublished\":\"2026-04-02T13:06:17+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolution-medicines-begins-treating-patients-in-phase-3-rasolute-303-trial-evaluating-daraxonrasib-as-first-line-treatment-for-patients-with-metastatic-pancreatic-cancer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolution-medicines-begins-treating-patients-in-phase-3-rasolute-303-trial-evaluating-daraxonrasib-as-first-line-treatment-for-patients-with-metastatic-pancreatic-cancer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolution-medicines-begins-treating-patients-in-phase-3-rasolute-303-trial-evaluating-daraxonrasib-as-first-line-treatment-for-patients-with-metastatic-pancreatic-cancer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4MzI1MyM3NDkzNTEyIzIxOTQwMzQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4MzI1MyM3NDkzNTEyIzIxOTQwMzQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolution-medicines-begins-treating-patients-in-phase-3-rasolute-303-trial-evaluating-daraxonrasib-as-first-line-treatment-for-patients-with-metastatic-pancreatic-cancer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Revolution Medicines Begins Treating Patients in Phase 3 RASolute 303 Trial Evaluating Daraxonrasib as First Line Treatment for Patients with Metastatic Pancreatic Cancer\u00a0\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Revolution Medicines Begins Treating Patients in Phase 3 RASolute 303 Trial Evaluating Daraxonrasib as First Line Treatment for Patients with Metastatic Pancreatic Cancer\u00a0 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-begins-treating-patients-in-phase-3-rasolute-303-trial-evaluating-daraxonrasib-as-first-line-treatment-for-patients-with-metastatic-pancreatic-cancer\/","og_locale":"en_US","og_type":"article","og_title":"Revolution Medicines Begins Treating Patients in Phase 3 RASolute 303 Trial Evaluating Daraxonrasib as First Line Treatment for Patients with Metastatic Pancreatic Cancer\u00a0 - Market Newsdesk","og_description":"REDWOOD CITY, Calif., April 02, 2026 (GLOBE NEWSWIRE) — Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it has begun treating patients in RASolute 303, a global Phase 3 clinical trial evaluating daraxonrasib as monotherapy and in combination with chemotherapy in patients with previously untreated metastatic pancreatic ductal adenocarcinoma (PDAC), a disease predominantly driven by oncogenic RAS variants. RASolute 303 is designed to enroll patients irrespective of tumor RAS genotype.\u00a0 \u201cStarting treatment of study participants in the RASolute 303 trial represents an important milestone for our daraxonrasib program and for patients with metastatic pancreatic cancer, a disease with substantial unmet medical need,\u201d said Alan Sandler, M.D., chief development officer of … Continue reading \"Revolution Medicines Begins Treating Patients in Phase 3 RASolute 303 Trial Evaluating Daraxonrasib as First Line Treatment for Patients with Metastatic Pancreatic Cancer\u00a0\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-begins-treating-patients-in-phase-3-rasolute-303-trial-evaluating-daraxonrasib-as-first-line-treatment-for-patients-with-metastatic-pancreatic-cancer\/","og_site_name":"Market Newsdesk","article_published_time":"2026-04-02T13:06:17+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4MzI1MyM3NDkzNTEyIzIxOTQwMzQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-begins-treating-patients-in-phase-3-rasolute-303-trial-evaluating-daraxonrasib-as-first-line-treatment-for-patients-with-metastatic-pancreatic-cancer\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-begins-treating-patients-in-phase-3-rasolute-303-trial-evaluating-daraxonrasib-as-first-line-treatment-for-patients-with-metastatic-pancreatic-cancer\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Revolution Medicines Begins Treating Patients in Phase 3 RASolute 303 Trial Evaluating Daraxonrasib as First Line Treatment for Patients with Metastatic Pancreatic Cancer\u00a0","datePublished":"2026-04-02T13:06:17+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-begins-treating-patients-in-phase-3-rasolute-303-trial-evaluating-daraxonrasib-as-first-line-treatment-for-patients-with-metastatic-pancreatic-cancer\/"},"wordCount":1079,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-begins-treating-patients-in-phase-3-rasolute-303-trial-evaluating-daraxonrasib-as-first-line-treatment-for-patients-with-metastatic-pancreatic-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4MzI1MyM3NDkzNTEyIzIxOTQwMzQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-begins-treating-patients-in-phase-3-rasolute-303-trial-evaluating-daraxonrasib-as-first-line-treatment-for-patients-with-metastatic-pancreatic-cancer\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-begins-treating-patients-in-phase-3-rasolute-303-trial-evaluating-daraxonrasib-as-first-line-treatment-for-patients-with-metastatic-pancreatic-cancer\/","name":"Revolution Medicines Begins Treating Patients in Phase 3 RASolute 303 Trial Evaluating Daraxonrasib as First Line Treatment for Patients with Metastatic Pancreatic Cancer\u00a0 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-begins-treating-patients-in-phase-3-rasolute-303-trial-evaluating-daraxonrasib-as-first-line-treatment-for-patients-with-metastatic-pancreatic-cancer\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-begins-treating-patients-in-phase-3-rasolute-303-trial-evaluating-daraxonrasib-as-first-line-treatment-for-patients-with-metastatic-pancreatic-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4MzI1MyM3NDkzNTEyIzIxOTQwMzQ=","datePublished":"2026-04-02T13:06:17+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-begins-treating-patients-in-phase-3-rasolute-303-trial-evaluating-daraxonrasib-as-first-line-treatment-for-patients-with-metastatic-pancreatic-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-begins-treating-patients-in-phase-3-rasolute-303-trial-evaluating-daraxonrasib-as-first-line-treatment-for-patients-with-metastatic-pancreatic-cancer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-begins-treating-patients-in-phase-3-rasolute-303-trial-evaluating-daraxonrasib-as-first-line-treatment-for-patients-with-metastatic-pancreatic-cancer\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4MzI1MyM3NDkzNTEyIzIxOTQwMzQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4MzI1MyM3NDkzNTEyIzIxOTQwMzQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-begins-treating-patients-in-phase-3-rasolute-303-trial-evaluating-daraxonrasib-as-first-line-treatment-for-patients-with-metastatic-pancreatic-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Revolution Medicines Begins Treating Patients in Phase 3 RASolute 303 Trial Evaluating Daraxonrasib as First Line Treatment for Patients with Metastatic Pancreatic Cancer\u00a0"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/948637","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=948637"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/948637\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=948637"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=948637"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=948637"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}